Cough clinical trials at UCSF
1 research study open to eligible people
Cough is a common symptom that everyone experiences. UCSF is recruiting participants for a study called ORV-PF-01 to learn about the effects of orvepitant on cough in patients with idiopathic pulmonary fibrosis. It is a two way, placebo controlled, cross-over study using two different doses of orvepitant. If you’re interested, contact UCSF to see if you qualify.
Showing trials for
Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
open to eligible people ages 40 years and up
ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.
San Francisco, California and other locations
Last updated: